The State Food and Drug Administration (SFDA) held a video conference on 22 June, 2009. Shao Mingli, the commissioner of SFDA made unified arrangements for intensifying the supervision of quality and safety of drugs and medical devices for A (H1N1) flu.

Shao Mingli said it was the first priority for food and drug regulatory departments at different levels to complete the setting objective for H1N1, which could be a completely difficult task. Organizations involved in technical review, on-site inspection and batch issue, should facilitate synchronous review and approval of products based on reliable quality. Shao Mingli required that the food and drug regulatory departments should enhance technical supervision, insist on strict requirements in drug authorization, manufacturing and testing and intensify the process control being consistent with its expected outcome. At the same time, it should be strengthened in products testing and post-marketing monitoring, and should be further improved ADR report system.

Shao Mingli emphasized that the food and drug regulatory departments should enforce the related laws and eliminate the potential quality and safety risks, intensify publicity and education, guide rational use of drug and medical device, and enhance public awareness.

Shao Mingli particularly emphasized that people involved in supervision or manufacturing must keep a clear mind, with scientific and rational attitude, to ensure the safety of vaccines.